Saturday, February 10, 2018 5:19:45 AM
On April 25, 2016, In the Court of Chancery of the State of Delaware, under C.A. No. 12255-VCG, styled Allan Breitkreuz and John Prosser II, Plaintiff v. Paul Parliament, Martin Wolfe, Douglas Brooks, and Bravo Multinational Corporation (sic) , Defendants , an action was commenced by the plaintiffs against the defendants alleging that the defendants purported to take over the registrant. The plaintiffs alleged that the defendants, in calling for a special meeting of the stockholders of the registrant, first violated Delaware law in purporting to remove the plaintiffs, both of whom had committed highly questionable acts detrimental to the registrant, and three other members of the registrant's board of directors, each of whom had caused serious harm to the registrant, and then, allegedly, the defendants purported to elect themselves as directors and officers of the registrant, even though Messrs. Parliament and Wolfe were already directors and officers of the registrant. The allegations of the plaintiffs are wholly without merit, and are contrary to the registrant's certificate of incorporation and bylaws, as amended, as well as the Delaware General Corporation Law. The defendants, including the registrant, will vigorously defend their position. A trial is expected to occur in late August 2016.. The defendants, including the registrant, have a hearing on a Motion for Summary Judgment on June 13, 2016. The registrant is not engaged in any other litigation at the present time, and management is unaware of any claims or complaints that could result in future litigation. Management will seek to minimize disputes with its customers but recognizes the inevitability of legal action in today’s business environment as an unfortunate price of conducting business
Recent BRVO News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:36:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 08:24:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:12:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:36:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:15:48 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/19/2023 08:31:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 12:27:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/28/2023 08:11:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:02:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/07/2023 08:03:17 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM